Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.680
-0.110 (-2.30%)
At close: Oct 3, 2024, 4:00 PM
4.650
-0.030 (-0.64%)
After-hours: Oct 3, 2024, 6:39 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for AQST stock have an average target of 9.29, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 98.50% from the current stock price of 4.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AQST stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $9 | Buy | Reiterates | $9 | +92.31% | Sep 30, 2024 |
| Leerink Partners | Leerink Partners | Buy Reiterates $10 → $12 | Buy | Reiterates | $10 → $12 | +156.41% | Sep 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +113.68% | Sep 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +92.31% | Aug 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $9 | Buy | Reiterates | $9 | +92.31% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
59.17M
from 50.58M
Increased by 16.97%
Revenue Next Year
58.92M
from 59.17M
Decreased by -0.42%
EPS This Year
-0.45
from -0.13
EPS Next Year
-0.50
from -0.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 62.4M | 80.9M | 92.8M | ||
| Avg | 59.2M | 58.9M | 76.8M | ||
| Low | 56.0M | 49.9M | 45.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.3% | 36.6% | 57.5% | ||
| Avg | 17.0% | -0.4% | 30.4% | ||
| Low | 10.6% | -15.7% | -23.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.40 | -0.30 | -0.27 | ||
| Avg | -0.45 | -0.50 | -0.31 | ||
| Low | -0.48 | -0.65 | -0.34 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.